Whitehawk Therapeutics (NASDAQ:WHWK) Issues Quarterly Earnings Results

Whitehawk Therapeutics (NASDAQ:WHWK) posted its quarterly earnings data on Thursday. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.21, FiscalAI reports.

Whitehawk Therapeutics Trading Up 0.3%

Whitehawk Therapeutics stock opened at $3.91 on Friday. Whitehawk Therapeutics has a 12 month low of $1.39 and a 12 month high of $4.48. The business’s 50 day simple moving average is $3.02 and its 200 day simple moving average is $2.48. The company has a market cap of $184.28 million, a price-to-earnings ratio of 8.32 and a beta of 0.51.

Institutional Trading of Whitehawk Therapeutics

Large investors have recently bought and sold shares of the company. KVP Capital Advisors LP bought a new stake in shares of Whitehawk Therapeutics in the fourth quarter valued at $5,242,000. Quadrature Capital Ltd purchased a new stake in Whitehawk Therapeutics in the 4th quarter worth about $28,000. Eversept Partners LP purchased a new stake in Whitehawk Therapeutics in the 4th quarter worth about $630,000. ADAR1 Capital Management LLC bought a new stake in Whitehawk Therapeutics in the 4th quarter valued at about $188,000. Finally, Marshall Wace LLP bought a new stake in Whitehawk Therapeutics in the 4th quarter valued at about $164,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

WHWK has been the topic of a number of research analyst reports. JonesTrading started coverage on Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price on the stock. Oppenheimer started coverage on Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $6.50.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.